The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 927-931

  Chakravarti, Arnab ^a   Dicker, Adam ^b   Mehta, Minesh ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

EGFR; Gliomas; Radiation

Indexed keywords

GROWTH KINETICS; MUTAGENESIS; PATIENT TREATMENT; RADIATION EFFECTS; SKIN;

EPIDERMAL GROWTH FACTOR RECEPTOR (EDFR); GLIOMAS;

ONCOLOGY;

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN RECEPTOR;

APOPTOSIS; CONFERENCE PAPER; CORRELATION ANALYSIS; DATA ANALYSIS; GENE AMPLIFICATION; GENE MUTATION; GLIA; GLIOMA; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 1242270613     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.092     Document Type: Conference Paper

References (38)

1. Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors Critical mediators of multiple receptor pathways . Curr Opin Cell Biol. 11:1999;184-189.
2. Zwick E., Hackel P.O., Prenzel N., Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci. 20:1999;408-412.
3. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:1999;241-250.
4. Wong A.J., Bigner S.H., Bigner D.D., Kinzler W.W., Hamilton S.R., Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 84:1987;6899-6903.
5. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 89:1992;6899-6903.
6. Humphrey P.A., Wong A.J., Vogelstein B., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factors in human glioblastoma. Proc Natl Acad Sci U S A. 87:1990;4207-4211.
7. Nagane M., Coufal F., Lin H., Bogler O., Cavenee W.K., Su Huang H.J. A common mutant epidermal growth factor receptor enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56:1996;5079-5086.
8. Nishikawa R., Furnari F.B., Lin H., et al. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res. 55:1995;1941-1945.
9. El-Obeid A., Bongcam-Rudloff E., Sorby M., Ostman A., Nister M., Westermark B. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. Cancer Res. 57:1997;5598-5604.
10. Nagane M., Levitzki A., Gazit A., Cavenee W.K., Huang H.J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-xl and caspase 3-like proteases. Proc Natl Acad Sci U S A. 95:1998;5724-5729.
11. Burrows R.C., Wancio D., Levitt P., Lillen L. Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron. 19:1997;251-267.
12. Maher E.A., Furnari F.B., Bachoo R.M., et al. Malignant glioma Ggenetics and biology of a grave matter . Genes Dev. 15:2001;1311-1333.
13. Miettinen P.J., Berger J.E., Meneses J., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 376:1995;337-341.
14. Threadgill D.W., Dlugosz A.A., Hansen L.A., et al. Targeted disruption of mouse EGF receptor Effect of genetic background on mutant phenotype . Science. 269:1995;230-234.
15. Sibilia M., Steinbach J.P., Stingl L., Aguzzi A., Wagner E.F. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17:1998;719-731.
16. Fricker-Gates R.A., Winkler C., Kirik D., Rosenblad C., Carpenter M.K., Bjorklund A. EGF infusion stimulates the proliferation and migration of embryonic progenitor cells transplanted in the adult rat striatum. Exp Neurol. 165:2000;237-247.
17. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62:2002;200-207.
18. Chakravarti A., Chakladar A., Delaney M.A., Latham D.E., Loeffler J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner. Cancer Res. 62:2002;4307-4315.
19. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929.
20. Lammering G., Lin P.S., Contessa J.N., Hampton J.L., Valerie K., Schmidt-Ullrich R.K. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys. 51:2001;775-784.
21. Lammerling G., Valerie K., Lin P.S., et al. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res. 7:2001;682-690.
22. O'Rourke D., Kao G.D., Singh N., et al. Conversion of a radio-resistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci U S A. 95:1998;10842-10847.
23. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through the continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62:2002;200-207.
24. Bos J.L. ras oncogenes in human cancer A review . Cancer Res. 49:1989;4682-4689.
25. Tuzi N.L., Venter D.J., Kumar S., Staddon S.L., Lemoine N.R., Gullick W.J. Expression of growth factor receptors in human brain tumours. Br J Cancer. 63:1991;227-233.
26. Guha A., Feldkamp M.M., Lau N., Boss G., Pawson A. Proliferation of human malignant astrocytomas is dependent on ras activation. Oncogene. 15:1997;2755-2765.
27. Guha A. Ras activation in astrocytomas and neurofibromas. Can J Neurol Sci. 25:1998;267-281.
28. Feldkamp M.M., Lau N., Guha A. Signal transduction pathways and their relevance in human astrocytomas. J Neurooncol. 35:1997;223-248.
29. Feldkamp M.M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects. Oncogene. 18:1999;7514-7526.
30. Feldkamp M.M., Lala P., Lau N., Roncari L., Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 45:1999;1442-1453.
31. Feldkamp M.M., Lau N., Roncari L., Guha A. Isotype-specific Ras-GTP levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of ras mutational status. Cancer Res. 61:2001;4425-4431.
32. Ding H., Roncari L., Shannon M., et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 61:2001;3826-3836.
33. Barker F.G., Simmons M.L., Chang S.M., et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 51:2001;410-418.
34. Etienne M.C., Formento J.L., Lebrun-Frenay C., et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res. 4:1998;2383-2390.
35. Korshunov A., Golanov A., Sycheva R., Pronin I. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas An analysis of 168 cases . J Clin Pathol. 52:1999;574-580.
36. Chakravarti A., Delaney M.A., Noll E., et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res. 7:2001;2387-2395.
37. Huhn S.L., Mohapatra G., Bollen A., Lamborn K., Prados M.D., Feuerstein B.G. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization Correlation with radiation treatment outcome . Clin Cancer Res. 5:1999;1435-1443.
38. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 93:2001;1246-1256.